Altai Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Altai Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-82,097	Closed	-$152K	–	7
2022 Q3	$152K	Sell	82,097 -17,903	-18%	-$53.4K	0.15%	8
2022 Q2	$307K	Hold	100,000	–	–	0.22%	10
2022 Q1	$722K	Hold	100,000	–	–	0.47%	11
2021 Q4	$1.64M	Hold	100,000	–	–	0.72%	11
2021 Q3	$995K	Hold	100,000	–	–	0.32%	13
2021 Q2	$998K	Hold	100,000	–	–	0.76%	9
2021 Q1	$996K	Buy	+100,000	New	+$1.03M	0.84%	7

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Altai Capital Management's PRDS Position: Q4 2022 in Review

Altai Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2022, closing a stake of 82,097 shares — an estimated $152K sold.

Altai Capital Management first reported a position in PRDS in Q1 2021 and held it in 7 quarters. The position peaked at $1.64M in Q4 2021. 65 funds tracked by Wall St. Rank hold PRDS as of Q4 2022.

Altai Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Altai Capital Management sold 82,097 Pardes Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $152K.
Altai Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Altai Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $1.64M in Q4 2021.
65 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2022.

Based on Altai Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.